Literature DB >> 3018242

Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers.

P S Portoghese, G Ronsisvalle, D L Larson, A E Takemori.   

Abstract

Bivalent ligands 1-4 with naltrexamine pharmacophores and spacers of different lengths containing a fumaryl moiety were synthesized and evaluated for mu and kappa opioid antagonist activity on the electrically stimulated guinea pig ileal longitudinal muscle (GPI). The fumaryl moiety was incorporated into the spacer in order to determine the effect of conformational restriction of the spacer on the relationship between spacer length and opioid antagonist potency. While it was found that the fumaryl and succinyl series (11) possessed a very similar structure-potency profile with respect to antagonism at mu opioid receptors, the interaction of these two series at kappa receptors differed substantially from one another. This difference was manifested by the longer spacer requirement for peak kappa antagonist potency in the fumaryl relative to the succinyl series. It is concluded that the conformational restriction imposed by the fumaryl group in a short spacer (n = 0) prevents effective interaction of both pharmacophores with vicinal recognition sites of the kappa receptor system; as the spacer is lengthened (n = 2) and becomes more flexible, the simultaneous occupation of vicinal recognition sites occurs with greater facility.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018242     DOI: 10.1021/jm00159a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Site-directed ligand discovery.

Authors:  D A Erlanson; A C Braisted; D R Raphael; M Randal; R M Stroud; E M Gordon; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.

Authors:  Shu-Husan Chou; Jen-Hsin Kao; Pao-Luh Tao; Ping-Yee Law; Horace H Loh
Journal:  Synapse       Date:  2012-03-31       Impact factor: 2.562

3.  Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.

Authors:  Morgan Le Naour; Mary M Lunzer; Mike D Powers; Philip S Portoghese
Journal:  J Med Chem       Date:  2012-01-05       Impact factor: 7.446

Review 4.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

5.  Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2007-04-04       Impact factor: 7.446

6.  Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Authors:  David J Daniels; Natalie R Lenard; Chris L Etienne; Ping-Yee Law; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

7.  Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.

Authors:  Bin Zhang; Tangzhi Zhang; Anna W Sromek; Thomas Scrimale; Jean M Bidlack; John L Neumeyer
Journal:  Bioorg Med Chem       Date:  2011-03-26       Impact factor: 3.641

8.  A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors.

Authors:  Shijun Zhang; Ajay Yekkirala; Ye Tang; Philip S Portoghese
Journal:  Bioorg Med Chem Lett       Date:  2009-11-04       Impact factor: 2.823

9.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

10.  Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.

Authors:  Morgan Le Naour; Eyup Akgün; Ajay Yekkirala; Mary M Lunzer; Mike D Powers; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.